PT93933A - Metodos e materiais para a expressao de plasminogenio humano em um sistema de celula eucariotica a que falta um activador de plasminogenio de sitio especifico - Google Patents

Metodos e materiais para a expressao de plasminogenio humano em um sistema de celula eucariotica a que falta um activador de plasminogenio de sitio especifico Download PDF

Info

Publication number
PT93933A
PT93933A PT93933A PT9393390A PT93933A PT 93933 A PT93933 A PT 93933A PT 93933 A PT93933 A PT 93933A PT 9393390 A PT9393390 A PT 9393390A PT 93933 A PT93933 A PT 93933A
Authority
PT
Portugal
Prior art keywords
plasminogen
cdc cdc
mmm
quot
cell
Prior art date
Application number
PT93933A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis J Castellino
Elliot David Rosen
Joann-Lynn Whitefleet-Smith
James Hugh Mclinden
Original Assignee
Univ Notre Dame Du Lac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Notre Dame Du Lac filed Critical Univ Notre Dame Du Lac
Publication of PT93933A publication Critical patent/PT93933A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT93933A 1989-05-01 1990-04-30 Metodos e materiais para a expressao de plasminogenio humano em um sistema de celula eucariotica a que falta um activador de plasminogenio de sitio especifico PT93933A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34580189A 1989-05-01 1989-05-01

Publications (1)

Publication Number Publication Date
PT93933A true PT93933A (pt) 1991-01-08

Family

ID=23356538

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93933A PT93933A (pt) 1989-05-01 1990-04-30 Metodos e materiais para a expressao de plasminogenio humano em um sistema de celula eucariotica a que falta um activador de plasminogenio de sitio especifico

Country Status (6)

Country Link
EP (1) EP0467987A4 (ja)
JP (1) JPH05500748A (ja)
AU (1) AU647391B2 (ja)
FI (1) FI915149A0 (ja)
PT (1) PT93933A (ja)
WO (1) WO1990013640A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US6099831A (en) * 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
EP1337548B1 (en) 2000-11-28 2008-07-16 David M. Waisman Anti-angiogenic polypeptides
WO2002050290A1 (en) * 2000-12-21 2002-06-27 Thromb-X Nv A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CA2514873C (en) 2002-12-13 2012-01-03 David Waisman Compositions and methods for inhibiting tumor growth and metastasis
US20120220015A1 (en) * 2009-05-26 2012-08-30 Biolex Therapeutics Compositions and methods for production of aglycosylated plasminogen
JP5819293B2 (ja) 2009-07-10 2015-11-24 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
WO2012093132A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
AU2012296884B2 (en) 2011-08-12 2015-02-05 Thrombogenics N.V. Plasminogen and plasmin variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943245A (en) * 1974-02-14 1976-03-09 Armour Pharmaceutical Company Purification of plasminogen
DE3065190D1 (en) * 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector

Also Published As

Publication number Publication date
EP0467987A1 (en) 1992-01-29
EP0467987A4 (en) 1992-07-08
WO1990013640A1 (en) 1990-11-15
FI915149A0 (fi) 1991-10-31
AU647391B2 (en) 1994-03-24
JPH05500748A (ja) 1993-02-18
AU5659690A (en) 1990-11-29

Similar Documents

Publication Publication Date Title
JP4426650B2 (ja) 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
JP4722989B2 (ja) 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
US6201104B1 (en) Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
CN1145636A (zh) 血管内皮生长因子2
JPH02442A (ja) エリトロポエチンを発現するヒトｃＤＮＡのクローニング方法
JPH11503901A (ja) インターロイキン−１β転換酵素様アポトーシスプロテアーゼ−３および４
PT93933A (pt) Metodos e materiais para a expressao de plasminogenio humano em um sistema de celula eucariotica a que falta um activador de plasminogenio de sitio especifico
JPH10508742A (ja) ヒトケモカインポリペプチド
US7282351B2 (en) Prostatic growth factor
JP3670665B2 (ja) 単球走化性蛋白質−４
WO1996018730A1 (en) Prostatic growth factor
JPH10500301A (ja) マクロファージ遊走阻止因子−３
JPH10513355A (ja) ヒトケモカインβ−１１およびヒトケモカインα−１
US5087572A (en) Dna encoding human plasminogen modified at the cleavage site
JP2003047483A (ja) インターロイキン−６スプライス変異体
JPH10504441A (ja) Ｔｎｆ形成阻害のための組成物およびその使用
US5190756A (en) Methods and materials for expression of human plasminogen variant
JP2002085082A (ja) スーパーオキシドジスムターゼ−４
JPH11501802A (ja) ユビキチン結合酵素７、８および９
JPH11507809A (ja) ヒト肝ガン由来増殖因子−２
US7416855B2 (en) Immunoassay methods for detecting interleukin-1 β converting enzyme like apoptosis protease-3
KR100506571B1 (ko) 플라스미노겐으로부터유래된맥관형성억제펩타이드
JP2000506371A (ja) 成長因子ｈｔｔｅｒ３６
JP2006087443A (ja) トランスフォーミング増殖因子αＨＩＩ

Legal Events

Date Code Title Description
FC3A Refusal

Effective date: 19960226